white → brown1
Citation noticeOur citation system is being overhauled
References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.
Dichloropane
(−)-2β-Carbomethoxy-3β-(3,4-dichlorophenyl)tropane
RTI-111, O-401Open in Piru
Dichloropane (RTI-111) is the 3β-(3′,4′-dichloro) phenyltropane analogue reported to inhibit [3H]WIN 35,428 binding to the dopamine transporter with an IC50 of 0.79 nM1. It lacks cocaine’s local anesthetic properties and is reported to have a slower onset and longer overall duration, with less pronounced rush and a more protracted comedown. The substance first appeared in limited quantities on the online research chemical market around 2010. Its pharmacology, metabolism, and toxicity remain poorly characterized.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Threshold3 mg
Light5-10 mg
Moderate10-20 mg
Strong20-40 mg
Heavy60+ mg
Duration
Onset15-30 minutes
Come Up15-30 minutes
Peak60-90 minutes
Offset60-90 minutes
Total2-4 hours
Subjective Effects
Subjective Effects not written up yet
Pharmacology
Pharmacodynamics
Dichloropane acts as a serotonin-norepinephrine-dopamine reuptake inhibitor, blocking SERT, NET, and DAT and thereby increasing monoamine signaling in synapses. It has greater relative affinity for the serotonin and norepinephrine transporters than for the dopamine transporter compared with cocaine.
Pharmacokinetics
Absorption & half-lifenot documented yetMetabolitesnone documented yet
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Tolerance to many effects develops with prolonged, repeated use, leading to increasingly large doses being needed to produce the same effects.
Tolerance returns to baseline after about 1–1.5 weeks without further consumption.
Tolerance takes about 2–4 days to reduce by half.
Possible cross-tolerance with all dopaminergic stimulants; after dichloropane use, stimulants may have reduced effects.
Harm Potential
Addiction & Dependence
Psychological
ModerateChronic use is considered moderately addictive and has high abuse potential. Some users may develop psychological dependence, and once dependence is established, abrupt cessation may lead to cravings and withdrawal effects.
Physical
ModerateRegular or extended use may lead to physical dependence similar to cocaine. Discontinuation can produce a 'crash' along with withdrawal symptoms including paranoia, depression, anxiety, mood swings, irritability, fatigue, insomnia, nausea, and intense cravings. These symptoms can persist for weeks or months.
Toxicity
Due to structural similarity to cocaine, high doses may present serious cardiac risks including sudden cardiac death from effects on cardiac sodium channels; chronic use may potentially result in cardiomyopathy similar to that seen with long-term cocaine use.
Regular insufflation is suspected to cause adverse effects on the nostrils, nose, and nasal cavities including loss of smell, nosebleeds, difficulty swallowing, hoarseness, and chronically runny nose.
Extended use or abuse is likely to cause both short and long-term downregulation of monoamine receptor systems.
Psychosis Risk
While little is known specifically about dichloropane's ability to induce psychosis due to its limited history of human use, it is reasonable to assume similar risks to cocaine and other dopaminergic stimulants when abused at high doses or for prolonged periods. Some users report symptoms similar to schizophrenia including scattered or incoherent thinking, as well as tactile hallucinations described as 'coke bugs'.
History & Culture
Dichloropane first appeared on the online research chemical market around 2010, among the earliest cocaine analogs offered there and only in limited quantities. Its subsequent history of human use remained brief.…
Legality
By Country
Illegal2
United StatesIllegal (analog/blanket ban)Controlled Substances Act, 21 U.S.C. §§ 802(32), 813, 841, and 844; §§ 802(32) and 813 added by the Controlled Substance Analogue Enforcement Act of 1986151617181920721225123242526
Dichloropane is not separately named in the DEA alphabetical controlled-substances list dated 27 August 2026. Under the Controlled Substances Act, it is federally covered by the controlled substance analogue provisions only when it satisfies the definition in 21 U.S.C. § 802(32), falls outside the statutory exclusions, and is intended for human consumption under § 813. In those circumstances, it is treated as a Schedule I controlled substance for federal-law purposes: possession is governed by § 844, while manufacture, distribution, dispensing, and possession with intent to manufacture, distribute, or dispense are governed by § 841. No DEA determination, scheduling rule, or federal judicial opinion categorically adjudicates dichloropane itself as a controlled substance analogue. These provisions concern federal law only.
SwitzerlandIllegalVerordnung des EDI vom 30. Mai 2011 über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien (Betäubungsmittelverzeichnisverordnung, BetmVV-EDI), Anhang 6, Verzeichnis e121314
Dichloropane, named as Dichloropan with its systematic chemical identity, is listed as item 239 in Annex 6, Verzeichnis e, of the Betäubungsmittelverzeichnisverordnung (BetmVV-EDI). Verzeichnis e substances are subject to the control measures applicable to Verzeichnis a narcotics, and their cultivation, manufacture, import, export, storage, use, or placing on the market requires authorization from the Federal Department of Home Affairs. Unauthorized conduct is punishable by up to three years' imprisonment or a monetary penalty.
Controlled / restricted1
GermanyRestrictedGesetz gegen Doping im Sport (Anti-Doping-Gesetz - AntiDopG), §§ 2-3, in conjunction with Anlage I des Internationalen Übereinkommens gegen Doping im Sport (2026 Prohibited List, BGBl. 2025 II Nr. 312)234567891011
Dichloropane, also known as RTI-111, falls within section S6.B of the 2026 Prohibited List as a stimulant with biological effects similar to listed stimulants. In conjunction with §§ 2-3 of the Anti-Doping Act, this classification restricts its manufacture, trade, supply, prescription, and administration for doping in human sport. Self-administration, participation in competition following such use, and acquisition or possession are prohibited when undertaken without medical indication to gain an advantage in organized-sport competition; these restrictions took effect on 1 January 2026 and do not establish a general prohibition on possession or use outside their sport-doping conditions.
References
Source Pages
Citations
Further Reading
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass reviewPending
Not yet reviewed: this article is pending editorial review by Lyrea.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the Dichloropane article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.
